Understand the source comparison
GHRP-2 Acetate News 2026: Formulation Comparison
The table below compares GHRP-2 acetate formulations against standard lyophilised GHRP-2 and alternative growth hormone secretagogues based on 2026 stability data, receptor selectivity profiles, and regulatory considerations. GHRP-2 Acetate 91–94% potency rete
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares GHRP-2 acetate formulations against standard lyophilised GHRP-2 and alternative growth hormone secretagogues based on 2026 stability data, receptor selectivity profiles, and regulatory considerations.
- GHRP-2 Acetate
- 91–94% potency retention
- GHS-R1a (0.7 nM affinity)
- CD36 scavenger receptor (180 nM)
- 503B compounding oversight required
- Best choice for multi-site studies requiring shipping intervals; acetate buffering reduces pH-driven degradation
- Standard Lyophilised GHRP-2
- 76–82% potency retention
- Adequate for single-site controlled studies with strict cold-chain; lower cost but higher degradation risk
- GHRP-6
- 68–74% potency retention
- GHS-R1a (0.4 nM affinity)
- No significant secondary binding identified
- Higher GHS-R1a affinity but poorer stability profile; greater GH pulse amplitude but inferior for extended protocols
- Ipamorelin
- 88–91% potency retention
- GHS-R1a (2.1 nM affinity)
- Minimal off-target activity
- Most selective GHS-R1a agonist; ideal when isolating GH-dependent effects without CD36 or other pathways
- MK-677 (Ibutamoren)
- Oral bioavailability; not applicable
- None characterized
- Investigational New Drug (IND). Not approved for human use
- Orally active but lacks acetate stability benefits; research use restricted to IND protocols in most jurisdictions